Sniffing out cancer is as easy as breathing

A team of EU-funded researchers has developed an accurate and non-invasive way to detect cancer through a person's breath. The hand-held sensor can be used by anyone without medical supervision in combination with their smart phone. Tests reveal the accuracy of the sensor is about 93 %.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


  Infocentre

Published: 15 January 2020  
Related theme(s) and subtheme(s)
Health & life sciencesHealth systems & management  |  Major diseases  |  Medical research
Industrial researchNanotechnology
Information societyInformation technology
Innovation
NanotechnologyNanomaterials  |  Nanomedicine
Research policyHorizon 2020
Special CollectionsCancer
Countries involved in the project described in the article
Austria  |  Finland  |  Germany  |  Ireland  |  Israel  |  Latvia
Add to PDF "basket"

Sniffing out cancer is as easy as breathing

Image

© andranik123 #289020801, source:stock.adobe.com 2020

Early detection and regular screening for cancer can save many lives. However, such services have traditionally required booking hospital appointments and tests, sometimes weeks in advance. In most cases, delays in diagnosis and treatment mean the disease becomes harder to treat.

To address these issues, the EU-funded SNIFFPHONE project has developed an innovative system that can detect gastric cancers. The project team has built and refined a prototype hand-held device through which a person’s breath is captured by an array of highly sensitive chemical sensors made from nanomaterials.

The results are recorded, stored and pre-processed by the breath analyser, which is connected via Bluetooth to a user’s smart phone. This allows the information to be transferred wirelessly via an internet connection to a remote external server.

Using statistical pattern recognition, the data is interpreted to create a clinical report which includes the screening results and personal information such as a patient’s age and weight. This file is then sent to the attending doctor who can advise on the next course of action for the patient.

A pivotal change

A mobile phone app provides instructions on how to use the breath analyser and instantly delivers the results back to the user. Meanwhile, healthcare professionals can use the project’s web application to search and select patients, view results over time, and check the status of the disease.

‘The most essential breakthrough is the ability of our device to discriminate cancer patients from healthy volunteers with an accuracy of about 93 %,’ explains project scientific director Dr Gidi Shani from Technion – the Israel Institute of Technology.

Project team leader Prof. Hossam Haick adds: ‘The value of early detection cannot be over-estimated in the fight against cancer – and if we can make check-ups inexpensive, effortless and comfortable we can increase their public uptake and so instigate a pivotal change in the toll cancer takes on humanity.’

As well as pre-screening, the project’s breath analyser could be used as a diagnostic tool for ongoing treatment. Patients can provide any number of samples during the day, wherever they are, cutting down on the need to visit the hospital or doctor’s surgery. The amount of data generated through regular tests can be automatically processed and analysed to provide an attending physician with a comprehensive surveillance report.

New project and trials

The project consortium brought together research and development teams, clinicians, four European SMEs and a large industrial company from six countries. Although SNIFFPHONE finished in February 2019, the work continues through another EU-supported project called VOGAS.

‘Through VOGAS, we will make further assessments of our prototype and additional modifications,’ adds Haick. ‘We will also examine how the effectiveness of the technology varies when trials are performed in different parts of the world.’

VOGAS also gives the project team an opportunity to explore the commercial potential of their technology. This will be achieved through the large clinical trials scheduled to take place in Latvia, Ukraine, Brazil, Chile and Columbia.

The SNIFFPHONE consortium was awarded the 2018 Innovation Award by the European Commission for most innovative project.

Project details

  • Project acronym: SNIFFPHONE
  • Participants: Israel (Coordinator), Germany, Finland, Austria, Latvia, Ireland
  • Project N°: 644031
  • Total costs: € 5 806 455
  • EU contribution: € 5 806 455
  • Duration: February 2015 to February 2019

See also

 

Convert article(s) to PDF

No article selected




loading
Print Version
Share this article
See also
Project details